3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Dermatologic
2
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
Peripheral Blood Stem Cell Transplantation
23
fludarabine phosphate
20
Cyclophosphamide
18
Mycophenolic Acid
16
Whole-Body Irradiation
15
Cyclosporine
15
Busulfan
12
Tacrolimus
11
Methotrexate
10
Antilymphocyte Serum
9
Radiotherapy
8
Melphalan
8
Etoposide
8
pembrolizumab
7
Methylprednisolone
6
Filgrastim
6
Sirolimus
4
Prednisone
4
Nivolumab
4
sargramostim
3
Vincristine
3
Transplantation
3
Therapeutics
3
Polymerase Chain Reaction
3
Cord Blood Stem Cell Transplantation
3
Amplified Fragment Length Polymorphism Analysis
3
mogamulizumab
2
merphos
2
bempegaldesleukin
2
Voriconazole
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recurrence
×
bempegaldesleukin
×
Dermatologic
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts
NCT03435640
2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2
Terminated
64 enrolled
22 charts